A retrospective study analyzed 21,080 patients undergoing oesophagectomy, revealing that desflurane anaesthesia resulted in lower rates of respiratory complications and ventilatory failure compared to sevoflurane and propofol. Patients receiving sevoflurane and propofol had significantly higher incidences of respiratory issues, with odds ratios of 1.13 and 1.43, respectively. Additionally, in-hospital mortality rates were lowest in the […]

In an analysis of 1887 patients with gastro-oesophageal cancer, only those with a partial response to neoadjuvant FLOT chemotherapy showed significant improvements in disease-free survival (DFS) and overall survival (OS) when treated with adjuvant FLOT. Patients categorized as minimal responders or complete responders did not benefit from additional chemotherapy. This study suggests that assessing pathological […]

A prospective study involving 123 esophageal squamous cell carcinoma patients demonstrates that post-treatment circulating tumor DNA (ctDNA) and PET/CT metrics can effectively differentiate those with pathological complete response (pCR) from non-pCR patients. The model, integrating ctDNA concentration and mean standardized uptake value (SUVmean), achieved areas under curves of 0.860 and 0.798 in discovery and validation […]

A study reveals that minimally invasive esophagectomy (MIE) and robotic-assisted minimally invasive esophagectomy (RAMIE) significantly reduce postoperative pain and pulmonary infections compared to traditional surgery. Both techniques, requiring specialized training, demonstrate improved short-term outcomes and comparable oncological results to open esophagectomy. The robotic-assisted approach offers potential additional benefits pending further randomized controlled trials, suggesting a […]

Oligometastatic patients with esophageal, gastro-esophageal junction, and gastric cancers experience improved outcomes with aggressive multimodal therapies. Research indicates that combining systemic therapy with surgical resection of primary tumors and metastases enhances prognosis. Notably, patients with oligometastatic cancer at the esophago-gastric junction showed potential for curative treatment. These findings suggest that current treatment paradigms should be […]

Recent advancements in immunotherapy provide new treatment avenues for advanced esophageal cancer, particularly for squamous cell carcinoma and esophagogastric adenocarcinoma. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are now approved in various treatment settings, including adjuvant therapy for patients post-surgery and first-line treatments combined with chemotherapy. These developments improve accessibility to effective therapies, regardless […]

Recent findings reveal that immune checkpoint inhibitors (ICIs) significantly improve treatment outcomes for advanced gastric adenocarcinoma (GAC), especially in patients with specific molecular subtypes such as MSI-H and HER2-positive. Combining ICIs with chemotherapy or targeted therapies enhances efficacy, despite the risk of immune-related adverse events (IRAEs). The study emphasizes the need for effective management strategies […]

A nutrition-based nomogram has been developed to predict the risk of intra-abdominal infection (IAI) after D2 radical gastrectomy for gastric cancer. An analysis of 404 patients identified key indicators, including the NRS2002 score, fasting blood glucose, and multi-visceral resection, associating them with IAI risk. The nomogram demonstrated good predictive capacity (AUROC 0.744) and excellent calibration, […]